The pharmaceutical company agreed Friday after the market closed to pay the U.S. Department of Justice and other agencies over the classification of its EpiPen Auto-Injector.
At issue was whether the anti-allergy EpiPen should be classified as a generic or a brand-name drug under Medicaid Drug Rebate program.
Following news of the settlement, Raymond James analyst Elliot Wilbur upgraded Mylan’s shares to “strong buy” from “market perform,” citing valuation.
The “announced settlement with the Department of Justice (DOJ) over EpiPen rebates eliminates what has become a significant overhang on shares, enabling focus to now shift back to basic fundamentals vs. ongoing speculation over downside scenarios around EpiPen,” Wilbur told investors.
In August, the pharmaceutical company was scrutinized by lawmakers after consumers saw a sixfold increase for the auto-injector device, which can save the lives of people suffering severe allergic reactions.
“This agreement is another important step in Mylan’s efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters,” Heather Bresch, CEO of Mylan, said in a written statement.
Also Friday, Mylan lowered its full-year earnings forecast to between $4.70 and $4.90 a share, from its previous guidance of $4.85 to $5.15 a share.
Mylan’s stock is down more than 33 percent year to date.